Company news

BioRestorative Therapies, Inc. news in 2022

BioRestorative Therapies, Inc.'s news releases, calls and decks from 2022, newest first.

View company

BioRestorative Therapies Announces SBIR Phase I Grant to Explore the Therapeutic Effects of ThermoStem® Targeting Polycystic Ovary Syndrome as an Indication

December 5, 2022

BioRestorative Therapies Enters Agreement with Regenexx, Granting BRTX Exclusive License Rights for Intellectual Property Related to the Development and Commercialization of its BRTX-100® Disc Program to Treat Chronic Lumbar Disc Disease

December 4, 2022

BioRestorative Therapies Announces First Patient Enrolled for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 29, 2022

BioRestorative Therapies Announces Clinical Trial Contract with Second Site for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 21, 2022

BioRestorative Therapies Announces Clinical Site Initiation for the Company’s Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease (cLDD)

June 12, 2022

BioRestorative Therapies Hosts Principal Investigator Meeting for its BRTX-100® Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

April 28, 2022

BioRestorative Therapies Announces Selection of 10 Clinical Sites for its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease

April 17, 2022

BioRestorative Therapies Announces cGMP Cell Manufacturing Facility Certification

April 3, 2022

BioRestorative Therapies Announces Research Collaboration with Professor Tore Bengtsson to Evaluate Heat Production of its ThermoStem® Program

March 9, 2022

BioRestorative Therapies Announces Notice of Allowance on Key Patent for its BRTX-100® Disc Program

February 15, 2022

BioRestorative Therapies Announces it has Initiated its Phase 2 Clinical Trial to Treat Chronic Lumbar Disc Disease – Site Selection Underway

February 6, 2022

BioRestorative Therapies Announces Notice of Allowance for New Patent Application in Japan and Expansion of ThermoStem® IP Portfolio

February 1, 2022

BioRestorative Therapies Announces the Appointment of Robert Paccasassi to Vice President of Quality Assurance/Regulatory Compliance

January 10, 2022

BioRestorative Therapies Awarded an STTR Phase I Grant to Explore the Therapeutic Effects of PEG-Peptide Hydrogel-Encapsulated Hypoxic Bone Marrow Stem Cells

January 3, 2022

Decks in 2022